Neovasc Inc (NASDAQ:NVCN) announced its Neovasc Reducer™ was showcased in a “live case” broadcast to over 800 members at the Kardiologie Symposium 2018. The successful live case was presented by Professor Banai and Dr. Spyrantis in the Sana-Klinikum Lichtenberg.
Dr. Olaf Göing, one of the panelists during the live case session, expressed that the patient in this instance, like a growing count of patients, still had considerable angina after all medicinal treatment alternatives had been exhausted. There remains clearly a need to see to this patient population as their life quality is extremely poor and the burden on the healthcare structure is significant following the incidence of emergency room visits. Reducer marks as an innovative and important treatment option for people suffering from refractory angina.
Alexei Marko, the CEO of Neovasc, expressed that the live case and the drive in the post market study exhibit the continued strong performance of Reducer in Europe. As Dr. Göing’s comments indicate, they consider they are only starting to scratch the surface of this extremely serious condition.
The firm’s REDUCER-I Observational trial is a multi-center, multi-country, 3-arm trial collecting long-term report from patients implanted with the Reducer. This trial is expected to register up to 400 patients. Currently, 135 people have been registered across 20 facilities that are active in Belgium, Netherlands, United Kingdom, Switzerland, Italy and Germany.
The Kardiologie Symposium 2018 was planned for the 18th time. It was co-chaired by Dr. Göing and by Professor Falk. Neovasc marks as a specialty medical device firm that develops, markets and manufactures products for the fast growing cardiovascular marketplace. Its offerings comprise the Reducer, for the cure of refractory angina which is not presently available in the U.S. and has been offered in Europe since 2015. Another product is the Tiara™ targeting mitral valve disease, which as of now is under investigation in the U.S., Canada and Europe.
THE MORNING REPORT
Start your workday the right way with the news that matters most.